Abstract: Growing evidence suggests that esculetin, a 5-lipoxygenase inhibitor, has pharmacotherapeutic potential due to its various pharmacological properties, such as potent anti-inflammatory, anti-nociceptive, and γ-aminobutyric acid type A (GABA_A) receptor partial agonist activities. However, the effects of this promising agent on migraine remain unexplored. This study therefore examined the impact of esculetin on relevant mechanisms in migraine-like conditions in rats. The systemic effects of esculetin at three distinct doses (5, 10, and 20 mg/kg) were tested in a nitroglycerin (NTG)-induced migraine model using in vivo experimental sets. The direct action of esculetin on the release of calcitonin gene-related peptide (CGRP) from critical structures of the trigeminovascular system (trigeminal ganglion, trigeminal nucleus, and meningeal afferents) was also tested in ex vivo experimental sets. Sumatriptan was used as a positive control in both sets of experiments. The in vivo results showed that esculetin reduced NTG-induced mechanical hyperalgesia and decreased trigeminal CGRP and cellular Fos proto-oncogene (c-Fos) levels. It also decreased degranulation and meningeal mast cell numbers. The ex vivo results revealed that esculetin reduced NTG-stimulated CGRP release from trigeminovascular explants, with the exception of meningeal explants. Sumatriptan reversed the NTG-induced changes in both experimental sets. Our findings suggest that esculetin exhibits anti-nociceptive activities in experimental migraine conditions, alleviating trigeminovascular CGRP concentrations and the degranulation of meningeal mast cells. esculetin may thus represent a therapeutic option for relieving migraine headaches, although further research is needed to confirm this.

秦皮乙素可通过抑制降钙素基因相关肽（CGRP）和调节脑膜肥大细胞减轻大鼠偏头痛样疼痛

[1]Baranoglu KilincY, TorunIE, KilincE, 2024. D2 dopamine receptor-mediated mechanisms of dopaminergic system modulation in in vivo and in vitro experimental models of migraine. Eur J Neurosci, 59(6):1177-1193.

[2]BolayH, ReuterU, DunnAK, et al., 2002. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med, 8(2):136-142.

[3]CetinkayaA, KilincE, CamsariC, et al., 2020. Effects of estrogen and progesterone on the neurogenic inflammatory neuropeptides: implications for gender differences in migraine. Exp Brain Res, 238(11):2625-2639.

[4]ChengYJ, TianXL, ZengYZ, et al., 2021. Esculetin protects against early sepsis via attenuating inflammation by inhibiting NF-κB and STAT1/STAT3 signaling. Chin J Nat Med, 19(6):432-441.

[5]CitakA, KilincE, TorunIE, et al., 2022. The effects of certain TRP channels and voltage-gated KCNQ/Kv7 channel opener retigabine on calcitonin gene-related peptide release in the trigeminovascular system. Cephalalgia, 42(13):1375-1386.

[6]DanisA, Baranoglu KilincY, TorunIE, et al., 2023. Esculetin alleviates pentylenetetrazole-induced seizures, cognitive impairment and pro-inflammatory cytokines and suppresses penicillin-induced epileptiform activity in rats. Life Sci, 313:121300.

[7]FrederiksenSD, Bekker-Nielsen DunbarM, SnoerAH, et al., 2020. Serotonin and neuropeptides in blood from episodic and chronic migraine and cluster headache patients in case-control and case-crossover settings: a systematic review and meta-analysis. Headache, 60(6):1132-1164.

[8]Giménez-BastidaJA, González-SarríasA, Laparra-LlopisJM, et al., 2021. Targeting mammalian 5-lipoxygenase by dietary phenolics as an anti-inflammatory mechanism: a systematic review. Int J Mol Sci, 22(15):7937.

[9]JeongNH, YangEJ, JinML, et al., 2018. Esculetin from Fraxinus rhynchophylla attenuates atopic skin inflammation by inhibiting the expression of inflammatory cytokines. Int Immunopharmacol, 59:209-216.

[10]KilincE, DagistanY, KotanB, et al., 2017a. Effects of Nigella sativa seeds and certain species of fungi extracts on number and activation of dural mast cells in rats. Physiol Int, 104(1):15-24.

[11]KilincE, Guerrero-ToroC, ZakharovA, et al., 2017b. Serotonergic mechanisms of trigeminal meningeal nociception: implications for migraine pain. Neuropharmacology, 116:160-173.

[12]KilincE, DagistanY, KuknerA, et al., 2018. Salmon calcitonin ameliorates migraine pain through modulation of CGRP release and dural mast cell degranulation in rats. Clin Exp Pharmacol Physiol, 45(6):536-546.

[13]KilincE, ToreF, DagistanY, et al., 2020. Thymoquinone inhibits neurogenic inflammation underlying migraine through modulation of calcitonin gene-related peptide release and stabilization of meningeal mast cells in glyceryltrinitrate-induced migraine model in rats. Inflammation, 43:264-273.

[14]KilincE, AnkaraliS, TorunIE, et al., 2022. Receptor mechanisms mediating the anti-neuroinflammatory effects of endocannabinoid system modulation in a rat model of migraine. Eur J Neurosci, 55(4):1015-1031.

[15]KilincE, TorunIE, Baranoglu KilincY, 2024. Meningeal mast cell-mediated mechanisms of cholinergic system modulation in neurogenic inflammation underlying the pathophysiology of migraine. Eur J Neurosci, 59(9):2181-2192.

[16]KilincYB, KilincE, DanisA, et al., 2023. Mitochondrial metabolism related markers GDF-15, FGF-21, and HIF-1α are elevated in pediatric migraine attacks. Headache, 63(8):1076-1086.

[17]KimD, JeongS, LeeS, et al., 2025. Esculetin inhibits mast cell-mediated allergic inflammation and anaphylaxis by suppressing the FcɛRI signaling pathway (Abstract ID: 162178). J Pharmacol Exp Ther, 392(S3):100683.

[18]Koyuncu IrmakD, KilincE, ToreF, 2019. Shared fate of meningeal mast cells and sensory neurons in migraine. Front Cell Neurosci, 13:136.

[19]Labastida-RamírezA, Rubio-BeltránE, VillalónCM, et al., 2019. Gender aspects of CGRP in migraine. Cephalalgia, 39(3):435-444.

[20]Labastida-RamírezA, CaronnaE, GollionC, et al., 2023. Mode and site of action of therapies targeting CGRP signaling. J Headache Pain, 24:125.

[21]LeeCR, ShinEJ, KimHC, et al., 2011. Esculetin inhibits N-methyl-d-aspartate neurotoxicity via glutathione preservation in primary cortical cultures. Lab Anim Res, 27(3):259-263.

[22]LevyD, MoskowitzMA, 2023. Meningeal mechanisms and the migraine connection. Annu Rev Neurosci, 46:39-58.

[23]LiangCY, JuWH, PeiSM, et al., 2017. Pharmacological activities and synthesis of esculetin and its derivatives: a mini-review. Molecules, 22(3):387.

[24]NeichiT, KoshiharaY, MurotaSI, 1983. Inhibitory effect of esculetin on 5-lipoxygenase and leukotriene biosynthesis. Biochim Biophys Acta, 753(1):130-132.

[25]OkuboM, YamanakaH, KobayashiK, et al., 2010. Leukotriene synthases and the receptors induced by peripheral nerve injury in the spinal cord contribute to the generation of neuropathic pain. Glia, 58(5):599-610.

[26]OttossonA, EdvinssonL, 1997. Release of histamine from dural mast cells by substance P and calcitonin gene-related peptide. Cephalalgia, 17(3):166-174.

[27]RamachandranR, 2018. Neurogenic inflammation and its role in migraine. Semin Immunopathol, 40(3):301-314.

[28]RamachandranR, BhattDK, PlougKB, et al., 2014. Nitric oxide synthase, calcitonin gene-related peptide and NK-1 receptor mechanisms are involved in GTN-induced neuronal activation. Cephalalgia, 34(2):136-147.

[29]RasmussenRH, Jansen-OlesenI, KristensenDM, et al., 2022. Ex vivo release of calcitonin gene-related peptide from the trigeminovascular system in rodents. J Vis Exp, 183:e63723.

[30]RzodkiewiczP, GasinskaE, MaslinskiS, et al., 2015. Antinociceptive properties of esculetin in non-inflammatory and inflammatory models of pain in rats. Clin Exp Pharmacol Physiol, 42(2):213-219.

[31]RzodkiewiczP, GąsińskaE, GajewskiM, et al., 2016. Esculetin reduces leukotriene B4 level in plasma of rats with adjuvant-induced arthritis. Reumatologia, 54(4):161-164.

[32]SilvestroM, OrologioI, SicilianoM, et al., 2023. Emerging drugs for the preventive treatment of migraine: a review of CGRP monoclonal antibodies and gepants trials. Expert Opin Emerg Drugs, 28(2):79-96.

[33]SinghL, KaurA, GargS, et al., 2020. Protective effect of esculetin, natural coumarin in mice model of fibromyalgia: targeting pro-inflammatory cytokines and MAO-A. Neurochem Res, 45(10):2364-2374.

[34]SinghuberJ, BaburinI, EckerGF, et al., 2011. Insights into structure-activity relationship of GABA_A receptor modulating coumarins and furanocoumarins. Eur J Pharmacol, 668(1-2):57-64.

[35]Skalicka-WoźniakK, OrhanIE, CordellGA, et al., 2016. Implication of coumarins towards central nervous system disorders. Pharmacol Res, 103:188-203.

[36]Sureda-GibertP, Romero-ReyesM, AkermanS, 2022. Nitroglycerin as a model of migraine: clinical and preclinical review. Neurobiol Pain, 12:100105.

[37]TorunIE, KilincYB, KilincE, et al., 2024. TRESK channel activation ameliorates migraine-like pain via modulation of CGRP release from the trigeminovascular system and meningeal mast cells in experimental migraine models. Life Sci, 357:123091.

[38]WooTS, YoonSY, PenaICD, et al., 2011. Anticonvulsant effect of Artemisia capillaris Herba in mice. Biomol Ther, 19(3):342-347.

[39]WuKC, ChenYH, ChengKS, et al., 2013. Suppression of voltage-gated Na⁺ channels and neuronal excitability by imperatorin. Eur J Pharmacol, 721(1-3):49-55.

[40]YanJ, DussorG, 2014. Ion channels and migraine. Headache, 54(4):619-639.

[41]ZhangLL, XieQX, LiXF, 2022. Esculetin: a review of its pharmacology and pharmacokinetics. Phytother Res, 36(1):279-298.

[42]ZhangWY, MulatiaS, ZhangMM, et al., 2025. Esculetin inhibited fever, pain, and inflammatory responses via binding to HSC70. J Ethnopharmacol, 350:120022.

[43]ZhuLP, NangC, LuoF, et al., 2016. Esculetin attenuates lipopolysaccharide (LPS)-induced neuroinflammatory processes and depressive-like behavior in mice. Physiol Behav, 163:184-192.

Similar articles